Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • BioNTech sales and marketing update

    BioNTech AG, Mainz, Germany Business: Diagnostic BioNTech launched its CE-IVD MammaTyper test to stratify breast cancer patients by molecular subtype. The in vitro test based on RT-qPCR technology detects mRNA …

    Published on 8/10/2015
  • Castle Biosciences, FedMed Inc., Multiplan Inc., Preferred Medical Claim Solutions LLC sales and marketing update

    Castle Biosciences Inc., Friendswood, Texas FedMed Inc., Gaithersburg, Md. Multiplan Inc., New York, N.Y. Preferred Medical Claim Solutions LLC, Scottsdale, Ariz. Business: Diagnostic FedMed, Multiplan and Preferred …

    Published on 8/10/2015
  • Cellular Research sales and marketing update

    Cellular Research Inc., Palo Alto, Calif. Business: Genomics Cellular Research launched an early access program for its Whole Transcriptome Single Cell Precise Assays, which allows for the counting of the entire …

    Published on 8/10/2015
  • Daiichi Sankyo sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cardiovascular The U.K.s NICE issued draft guidance recommending Daiichis Lixiana edoxaban as an option to prevent stroke and systemic embolism in adults with…

    Published on 8/10/2015
  • GlaxoSmithKline, Centers for Disease Control and Prevention sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. U.S. Centers for Disease Control and Prevention, Atlanta, Ga. Business: Infectious The CDCs Advisory Committee on Immunization Practices (ACIP) issued a Category B …

    Published on 8/10/2015
  • Keryx sales and marketing update

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Business: Endocrine/Metabolic Keryx said two undisclosed national insurance providers added Auryxia ferric citrate to their Medicare D formularies. The oral …

    Published on 8/10/2015
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Endocrine/Metabolic Novartis said Germanys Federal Joint Committee (G-BA) issued an early benefit assessment stating that Signifor pasireotide provides …

    Published on 8/10/2015
  • Opko sales and marketing update

    Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK), Miami, Fla. Business: Diagnostic The National Comprehensive Cancer Network (NCCN) added Opkos 4Kscore as a recommended test to the 2015 NCCN Guidelines for Prostate Cancer …

    Published on 8/10/2015
  • Santen sales and marketing update

    Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan Business: Ophthalmic The U.K.s NICE issued preliminary recommendations requesting more information from Santen for Ikervis ciclosporin to treat severe keratitis …

    Published on 8/10/2015
  • Veracyte, Aetna sales and marketing update

    Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Diagnostic Veracyte said it will become part of Aetnas laboratory network. Veracyte administers Afirma, a …

    Published on 8/10/2015
  • Agilent sales and marketing update

    Agilent Technologies Inc. (NYSE:A), Santa Clara, Calif. Business: Diagnostic Agilent launched three tests for use on the SureSelect target enrichment technology for exome sequencing: Human All Exon V6, V6+UTR and V6+…

    Published on 8/3/2015
  • Danaher, Hologic sales and marketing update

    Danaher Corp. (NYSE:DHR), Washington, D.C. Hologic Inc. (NASDAQ:HOLX), Bedford, Mass. Business: Diagnostic The U.K.s NICE issued final guidance recommending against the Prostate Health Index (PHI) from Danahers Beckman …

    Published on 8/3/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisai launched Lenvima lenvatinib in the U.K. to treat patients with radioactive iodine refractory differentiated thyroid cancer. The compound is an inhibitor …

    Published on 8/3/2015
  • Ferring sales and marketing update

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer The U.K.s NICE issued draft guidance recommending against Firmagon degarelix from Ferring to treat advanced hormone-dependent prostate cancer. The …

    Published on 8/3/2015
  • Galena Biopharma sales and marketing update

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Business: Gastrointestinal Galena launched Zuplenz ondansetron oral soluble film in the U.S. to treat highly and moderately emetogenic chemotherapy-induced nausea and …

    Published on 8/3/2015
  • Genentech, Novartis, Roche sales and marketing update

    Genentech Inc., South San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Transplant, Dermatology The U.K.s NICE issued final guidance …

    Published on 8/3/2015
  • Gilead, AbbVie, Bristol-Myers sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Infectious The U.K.s NICE published three draft guidances …

    Published on 8/3/2015
  • Invitae sales and marketing update

    Invitae Corp. (NYSE:NVTA), San Francisco, Calif. Business: Genetics Invitae reduced the patient pay price to $475 from $1,500 per indication for its genetic tests. Invitae said the pay price is only for patients who …

    Published on 8/3/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cardiovascular, Endocrine/Metabolic Merck discontinued development of Liptruzet ezetimibe/atorvastatin, which is approved to treat atherosclerosis and dyslipidemia…

    Published on 8/3/2015
  • Mylan sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Inflammation Mylan launched Sirdupla salmeterol/fluticasone propionate in the U.K. to treat and prevent symptoms of asthma in adults. The pressurized metered-dose …

    Published on 8/3/2015
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic The German Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that no hint of added …

    Published on 8/3/2015
  • Pathway Genomics sales and marketing update

    Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway launched the BRCATrue Hispanic (8-Site) genetic testing panel worldwide to determine hereditary cancer risk in patients of Mexican and Hispanic …

    Published on 8/3/2015
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune The U.K.s NICE issued final guidance recommending Entyvio vedolizumab from Takeda to treat moderate to severely active ulcerative colitis (…

    Published on 8/3/2015
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer The U.K.s NICE issued preliminary draft guidance recommending against the use of Lynparza olaparib from AstraZeneca for maintenance treatment of ovarian…

    Published on 7/27/2015
  • Clinigen Group, Clovis sales and marketing update

    Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Business: Cancer Clinigen launched a European global access program for Clovis rociletinib to treat advanced non-…

    Published on 7/27/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993